There are numerous Research opportunities for Medicine residents to engage in at 51吃瓜黑料曝料 University. In addition to the research track, residents can opt to participate in a variety of research projects which may include basic, clinical, and translational investigation.
MCG Department of Medicine Research
| Medicine Departments within 10 positions of DoM | ||
| University of Nebraska | 57 | $18.5 |
| Rush Medical Center | 58 |
$17.3 |
| University of UConn | 59 | $16.8 |
| University of Louisville | 60 | $16.2 |
| University of Cincinnati | 61 | $15.5 |
| 51吃瓜黑料曝料 | 62 | $13.5 |
| Penn State | 63 | $13.2 |
| University of New Mexico | 64 | $12.4 |
| University of Kentucky | 65 | $11.6 |
| University of Hawaii | 66 | $11.5 |
| VCU | 67 | $11.3 |
The Translational Research Program of the Department offers support for mentor identification, project design, ancillary support (study coordinators and statistics), and research funding. Many residents use this pathway for getting involved in a meaningful project, but it is by no means the only option. Individual faculty are always amenable to working with motivated residents and also provide a rewarding research experience.
2023-2024
Standridge M, et al. 2023. Therapy related multiple myeloma: A distinct entity. Blood,142 (supplement 1): 6657.
Standridge M, et al. 2023. Prephase Cyclophosphamide: A advantage bridge to definitive therapy. Blood, 142 (supplement 1): 6316.
Desai S, Standridge M, et al. 2023. Eliminating racial disparities among transplant patients in multiple myeloma after referral to a tertiary center. Blood, 142 (supplement 1): 6659. 2023-190828
Matosz S, Standridge M, et al. 2023. Outcomes in acute lymphoid leukemia patients with incomplete hyper-CVAD cycles. Blood, 142 (supplement 1): 5887.
Dickey J, Standridge M et al. 2023. The overuse of C. difficile testing among autologous transplant patients with melphalan conditioning: a single center experience. Blood, 142 (supplement 1): 7065.
Standridge M, Desai S, Yerraguntla S, Bradshaw D, Mian M, Shah A, Kota V, Jillela A, Cortex J, Chauhan A, Kerakous A, and Bryan L. 2023. 鈥淧rephase Cyclophosphamide: A advantage bridge to definitive therapy.鈥�
